Disease Markers

Disease Markers / 2015 / Article

Research Article | Open Access

Volume 2015 |Article ID 343818 | https://doi.org/10.1155/2015/343818

Refik Pul, Özlem Yildiz, Franco Morbiducci, Thomas Skripuletz, Philipp Schwenkenbecher, Martin Stangel, Friedrich Götz, Georg Berding, Corinna Trebst, Frank Donnerstag, "CSF Levels of Angiopoietin-2 Do Not Differ between Patients with CSF Fluid Leakage Syndrome and Controls", Disease Markers, vol. 2015, Article ID 343818, 9 pages, 2015. https://doi.org/10.1155/2015/343818

CSF Levels of Angiopoietin-2 Do Not Differ between Patients with CSF Fluid Leakage Syndrome and Controls

Academic Editor: Natacha Turck
Received09 May 2015
Revised24 Aug 2015
Accepted25 Aug 2015
Published10 Sep 2015


CSF abnormalities have been reported in CSF leakage syndrome. However, the mechanism for these CSF changes is actually unknown and they may indicate impaired CSF flow or blood-CSF barrier. Angiopoietin-2 (Ang-2), a protein which is expressed and released by endothelial cells, has been associated with increased vascular permeability. In the assumption that CSF changes are due to an impaired blood-CSF barrier, we hypothesized that subjects with persistent CSF leakage may have increased CSF Ang-2 levels. We enrolled 10 subjects with a clinically definite diagnosis of persisting CSF leakage syndrome and 10 control subjects. In CSF analyses, CSF to serum albumin ratio (Qalb) was the most frequently increased parameter indicating a disturbed blood-CSF barrier function. Comparison of the mean CSF Ang-2 levels, CSF to serum Ang-2 ratio (QAng-2), and QAng-2/Qalb between the control and CSF leakage patients did not show any significant difference. We suggest that the increase of Qalb results from a low CSF flow. Future studies with phase contrast-MRI in conjunction with CSF analyses before and after epidural blood patch treatment are required to address this question. It would be of particular interest whether Qalb can be used as a marker for successful nontargeted epidural blood patch treatment.

1. Introduction

Persistent cerebrospinal fluid (CSF) leakage syndrome is a rare cause of chronic headache. The common clinical presentation is orthostatic headache of dull aching nature, which, according to the International Headache Society Classification, occurs or worsens in less than 15 minutes after assuming the upright position and disappears or improves in less than 30 minutes after recumbency [1]. While secondary CSF loss can be an aftermath of a trauma, neurosurgical procedure, or even systemic dehydration, the etiology of spontaneous (primary) CSF loss remains unknown. Suspected factors are an underlying weakness of the meningeal sac/diverticula in certain regions and a trivial trauma [1]. The concept of such “loci minoris resistentiae” is supported by the fact that generalized connective tissue disorders predispose to the formation of dural defects allowing CSF leakage into the epidural or subdural space [1]. These leakages most often occur at the level of the thoracic spine or cervicothoracic junction but rarely at the skull base [2]. Elevated leukocyte counts and protein concentrations in the CSF have been reported in several cases and were attributed to hydrostatic CSF pressure changes [1, 3]. The exact mechanism of these CSF changes is not well understood and they may indicate alterations in the CSF flow or blood-CSF barrier. The blood-CSF barrier is constituted by several barriers and one of them is the choroid plexus (CP), a highly vascularized endothelial-epithelial convolute in the ventricular system and the main source of CSF production [4]. Epithelial cells of the CP are interconnected via dense tight junction strands which shield the CSF from the blood. In contrast, endothelial cells embedded in the extracellular matrix of the CP are constitutively fenestrated [4]. This fenestrated phenotype has been shown to be maintained by vascular endothelial growth factor (VEGF) [5, 6]. A gatekeeper of VEGF function is angiopoietin-2 (Ang-2) and has been shown to breach the endothelial barrier function by counteracting the inhibitory effect of Ang-1 [7]. Ang-2 has been reported to be expressed in endothelial cells of the mouse and buffalo CP suggesting that Ang-2 together with Ang-1 and VEGF is involved in the regulation of CSF production [4, 8, 9]. Ang-2 has also been shown to be expressed by ependymal cells which, in contrast to epithelial cells of the CP, form a less tight “cellular barrier” between CSF and brain parenchyma [4, 10]. Interestingly, increased levels of CSF Ang-2 have been reported in hypoxemic patients or those with traumatic brain injury/subarachnoid hemorrhage suggesting that these resulted by disruption/increased permeability of the blood-CSF or CSF-brain parenchyma barrier [1113]. Less is known about Ang-2 in pathological conditions affecting the CSF compartment. We hypothesized that subjects with persistent CSF leakage may have altered CSF Ang-2 levels which may indicate an impaired or more permeable blood-CSF barrier, respectively.

2. Materials and Methods

In this study, 10 (8 female and 2 male) subjects with a clinically definite diagnosis of persisting CSF leakage syndrome were enrolled from February 2009 to April 2011 (http://www.ihs-classification.org/en/02_klassifikation/03_teil2/07.02.03_nonvascular.html). Beside the clinical symptoms, diagnosis was based on the findings in intrathecal gadolinium- (gd-) enhanced magnet resonance (MR) myelography and/or CSF scintigraphy (Table 1). For gd-enhanced MR myelography, gd (gadoterate meglumine, Dotarem, Guerbet, Villepinte, France) was injected intrathecally after obtaining informed consent. Subjects received a single dose of 0.2 mmol gd (≈0.4 mL 0.5 mmol/mL Gd-DOTA) and were maintained in a position of 35° head elevation. Conventional spin-echo sagittal and axial T1-weighted fat-suppressed sequences on a 1.5 T MR unit using a 35 mT/m gradient magnet (Siemens, Erlangen, Germany) enabled the detection of the site of the dural dehiscence. CSF scintigraphy was performed by administering 20 MBq (4.6 mCi) 111 indium-diethylene-triamine-pentaacetic acid via lumbar puncture. Images were obtained at 1 h and 4 h including the region of the urinary bladder and the area of lumbar puncture (posterior projection) after radioisotope injection. Early appearance of urinary bladder on the 4-hour image was noted (Table 1). At 24 and 48 h, images showed the activity distribution in the entire spinal subarachnoid space (dorsal projection) and the head (anterior, posterior, and both lateral projections). Images were obtained using large-field-of-view gamma cameras (DIACAM or ECAM, Siemens, Erlangen, Germany) equipped with medium-energy collimators. CSF and serum analyses were analyzed by standard methods before intrathecal administration of gd (Table 1) [14]. Ang-2 was measured in serum and CSF using the RayBio Human Ang-2 Elisa-Kit (Ray Biotech, distributed by Hoelzel Diagnostika GmbH, Köln, Germany) according to the manufacturer’s instructions. All conditions were tested in duplicate for each independent measurement. The study was approved by the Institutional Review Board of the Hannover Medical School. All participants signed an informed consent form detailing the purpose of this study, the tests included in the exploratory protocol, and the permission to revoke the obtained data. Statistical analysis was performed using GraphPad Prism version 5.02. Normality of data was assessed by the Shapiro-Wilk test. Since the control cohort did not show a normal distribution of data, we performed the two-tailed Mann-Whitney test to compare the mean Ang-2 values between the two cohorts. To analyze correlations to clinical measures two-tailed Pearson or Spearmen correlation coefficients were calculated. For each comparison, a value < 0.05 was considered as statistically significant.


SubjectsDemographic and clinical characteristics of subjects with CSF leakage
Age (years)GenderBMIRelevant comorbiditiesSymptomsOrthostatic symptomsDD (days)Prior traumatic eventOther events before disease onset

150f 24.7NoneHeadache left frontalYes30NoPhysical exertion
240f 18.4Marfan’s syndrome, Arnold-Chiari I malformation, and depressive disorderOccipital and temporal headacheYes14NoNo
343m26NoneOccipital headacheYes10NoNo
445f 23.7Migraine with auraOccipital headache, pressure feeling in left ear, diplopia, and paresthesia in left arm and legYes173NoNo
572f 14.7Subtotal colectomy, short bowel syndrome, cachexia, chronic gastritis, and numerous intestinal operations due to recurrent ileusOccipital headache, vertigoYes360NoNo
630f 21.5NoneHolocephalic headacheYes30NoNo
744m25.2Arterial hypertension Holocephalic headache, vertigo, vomiting, diplopia, and paresthesia in left arm and legYes196Fenestration of a spinal arachnoid cyst T2–4Decompression surgery due to disc herniation at the level of C5/6
823f 22.8NoneOccipital headache, vertigo, and photosensitivityYes4NoNo
944f 20.2NoneOccipital headache, vertigo, vomiting, and abducens nerve palsyYes2NoNo
1052f 23.4Cervical conisation due to cervix carcinoma and decompression surgery due to disc herniation at the level of L5/S1Holocephalic headacheProtracted202NoNo


SubjectsRadiological characteristics of subjects with CSF leakage
Method of detectionLevel of leakageCSF scintigraphyEarly detection (in the bladder)Meningeal enhancement (cranial MRI)Subdural effusions (cranial MRI)

1Intrathecal gadolinium enhanced MR myelographyC1/2, T12Not detectedYesYesYes
2Intrathecal gadolinium enhanced MR myelographyL1/2, L2/3n.d.n.a.n.d.Yes
3Intrathecal gadolinium enhanced MR myelographyC7/T1, T1/2C7/T1YesYesYes
4Intrathecal gadolinium enhanced MR myelographyC6/7, T1/2, T11, 12, L1/2, L3/4L1/2, L3/4, T11/12YesNoNo
5Intrathecal gadolinium enhanced MR myelographyC5/6, C6/7 (nerve root cysts L4/5, S2/3, S3)Not detectedYesYesYes
6Intrathecal gadolinium enhanced MR myelographyC1/2, C5/6, C6/7, T12/L1n.d.n.a.YesYes
7Intrathecal gadolinium enhanced MR myelography(Weak) C4/5, T1/2Not detectedYesNoYes
8Intrathecal gadolinium enhanced MR myelographyC7/T1, T1/2, T2/3n.d.n.a.YesYes
9Intrathecal gadolinium enhanced MR myelographyC6/7, T1/2n.d.n.a.YesYes
10MRI of the spineNot detected (multiple nerve root cysts, 10 mm T1/2 and 25 mm S1/2)S1/2NoYesYes


ControlsDemographic and clinical characteristics of control subjects
Age (years)GenderBMIDiagnosisRelevant comorbidities

174f20.6Axonal polyneuropathyArterial hypertension, atrial fibrillation
245m26.6Essential tremorAlcohol dependence, recurrent depressive disorder
348m27.2Multifocal motor neuropathyAtopic dermatitis
455f25.7Cervical vertigoDisc herniation at the level of T6/7, asthma
565m31.2Demyelinating neuropathyArterial hypertension, heart failure, psoriasis, gout
645f42.0Axonal polyneuropathyArterial hypertension, diabetes mellitus, asthma, and anxiety disorder
748f19.2Somatic symptom disorderDepressive disorder, anxiety disorder
831f28.7Axonal polyneuropathyBorderline personality disorder
924f20.5Somatic symptom disorderNone
1059m22.5Motor neuron diseaseNone

3. Results

Demographic and clinical characteristics of the enrolled subjects with persistent CSF leakage and those of controls are summarized in Table 1. Control subjects were recruited from an inpatient population admitted to the hospital with different neurological diagnoses. They were on average five years older (49 ± standard deviation (SD) 15 years) than subjects with CSF leakage (44 ± SD 13 years) and the proportion of females outweighed that of males in both groups. In general, patients with CSF leakage had a normal or almost normal body weight (mean body mass index (BMI) 22.1 ± SD 3.5), while the mean BMI of control subjects was higher (). We included this parameter since it has been shown to correlate positively with the CSF to serum albumin ratio, also referred to as Qalb, and a relationship with the epidural fat storage has been suggested [15]. Considering all participating subjects, we did not find any significant correlation of BMI to Qalb (Spearman , ). Exclusion of one outlier (CSF leakage subject number 5 with Qalb 48.5) did not result in a significant correlation either (Spearman , ).

Figure 1 shows characteristic findings in cranial MRI as well as the diagnostic procedure with intrathecal gd MR myelography (Figure 1). CSF scintigraphy resulted in the localization of the level of CSF leakages in 3 of 6 subjects, while MR myelography with intrathecal gd was more efficient with 9 of 9 subjects (Table 1). The early appearance of the radioisotope in the bladder enabled the diagnosis of CSF leakage in 5 of 6 subjects. Moreover, intrathecal gd MR myelography revealed additional CSF leakages in 3 subjects who had CSF leakages already detected by scintigraphy. Cranial MRI demonstrated subdural effusions in 9 of 10 subjects, while after the application of gd contrast agent meningeal enhancement was found in 7 of 9 subjects suggesting that subdural effusions are at least as reliable sign as meningeal contrast enhancement (Table 1).

Orthostatic headache, which mostly occurred occipitally, was a constant and most reliable symptom in all CSF leakage subjects. Despite the typical orthostatic nature of headache, time from onset of complaints to diagnosis varied considerably (mean time days, expressed as disease duration in Table 1) and in only two cases a traumatic event or a trigger was identified. In one of these subjects, CSF leakage was clearly attributed to a decompression surgery due to disc herniation at the level of C5/6 and fenestration of a spinal arachnoid cyst at the level of T2 to T4. Concerning relevant comorbidities, one subject in the CSF leakage cohort had Marfan’s disease as a predisposing factor for CSF leakage (Table 1).

CSF analyses revealed lymphocytic pleocytosis in 4 cases with a cell count up to 23 leukocytes per μL and CSF total protein was increased in 7 cases (normal range < 0.5 g/L). Qalb is a generally accepted measure of the blood-CSF barrier function and was increased in 7 subjects with CSF leakage [16]. In the control cohort, no subject revealed a CSF pleocytosis and the CSF total protein and Qalb were increased only in 4 and, respectively, in 3 cases. In each cohort, one subject exhibited type 2 oligoclonal bands, while in one subject of the CSF leakage cohort type 3 oligoclonal bands were detected. In none of the subjects, intrathecal immunoglobulin (Ig) G, IgA, or IgM synthesis was determined (Table 2).

CSF characteristicsAng-2
Cell count
per µL
CytologyCSF total protein (mg/L)Qalb
(CSF/serum × 103)
Blood-CSF barrier functionIgG
Oligoclonal bandsLactate
(CSF/serum × 103)


115.3LP111013.2ImpairedNoNoNoType IIn.d.106.88.1
223.0LP8968.8ImpairedNoNoNoType I1.8193.021.9
315.0LP102118.7ImpairedNoNoNoType III1.7403.621.6
41.3N4765.9IntactNoNoNoType I1.6203.634.5
50.3ABC290048.5n.a.NoNoNoType In.d.46.60.96
66.7LP3654.8IntactNoNoNoType In.d.803.9167.5
73.0N103315.4ImpairedNoNoNoType I1.5584.438.0
80.3ABC104417Impairedn.a.n.a.n.a.Type I1.8418.624.6
92.0N7299.9ImpairedNoNoNoType I2.0105.910.7
103.0N5629.5ImpairedNoNoNoType I1.7542.457.3


10.7N4045.3IntactNoNoNoType I1.7218.341.5
21.0N4136.3IntactNoNoNoType I1.9235.837.7
32.3N79614.8ImpairedNoNoNoType I2.0222.415.1
40.3N3775.4IntactNoNoNoType I1.4633.5116.5
53.3N5349.2ImpairedNoNoNoType II1.7254.427.5
60.3N65410.1ImpairedNoNoNoType I2.9332.532.8
71.0ABC2363.5IntactNoNoNoType I1.8175.350.4
81.3N3455.7IntactNoNoNoType I1.5243.543.1
93.3N3384.4IntactNoNoNoType I1.6443.1101.4
100.3N5067.2IntactNon.d.NoType I1.3371.051.5

The mean CSF Ang-2 concentration of all subjects was 0.31 ± SD 0.15 pg/mL without any difference between control and CSF leakage subjects (control 0.27 ± SD 0.09 pg/mL versus CSF leakage subjects 0.35 ± SD 0.20 pg/mL, , ; Tables 2 and 3). The mean serum Ang-2 concentration of all subjects (1.23 ± SD 0.84 pg/mL) was approximately four times higher than the mean CSF Ang-2 concentration and again we did not detect any difference between the control and CSF leakage subjects (control 1.01 ± SD 0.49 pg/mL versus CSF leakage subjects 1.46 ± SD 1.10 pg/mL, , ; Tables 2 and 3). The comparison of the CSF to serum ratio multiplied by 103 of Ang-2 (expressed as QAng-2 in Tables 2 and 3) did not result in any statistical difference (control 313.0 ± SD 138.9 versus CSF leakage subjects 340.9 ± SD 249.8, , ). Normalizing of QAng-2 by dividing by Qalb (QAng-2/Qalb) did not yield a statistical difference either (control 51.74 ± SD 32.19 versus CSF leakage subjects 38.52 ± SD 48.15, , ; Tables 2 and 3). Moreover, there were no significant correlations of QAng-2 (Spearman , ) and CSF Ang-2 concentrations (Spearman , ) with Qalb. CSF IgG, IgA, and IgM concentrations and CSF albumin did not correlate with CSF Ang-2 concentrations or QAng-2 either (data not shown).

Median25% percentile75% percentileMedian25% percentile75% percentile

Cell count3.001.0515.081.000.302.550.092
CSF total protein (g/L) 0.740.451.020.410.340.560.063
CSF lactate (mmol/L) 1.741.571.831.731.441.880.625

Mean CSF Ang-2 (pg/mL)0.330.210.430.250.220.310.272
Mean serum Ang-2 (pg/mL)1.040.762.000.930.581.360.405

IgG ratio7.904.4310.642.992.446.560.036
IgA ratio4.402.667.071.771.322.980.013
IgM ratio1.601.002.720.480.350.720.002

We did not detect any difference in mean CSF lactate concentrations between the two cohorts (control 1.8 ± SD 0.5 mmol/L versus CSF leakage subjects 1.7 ± SD 0.2 mmol/L, , ; Tables 2 and 3). However, we found significant negative correlations for QAng-2 (Spearman , ) and QAng-2/Qalb (Spearman , ) with CSF lactate concentrations, while there was no significant correlation for CSF Ang-2 with CSF lactate concentration (Spearman , ). There were no significant relationships when cell count was correlated with CSF Ang-2 concentrations, QAng-2, or QAng-2/Qalb (Spearman ranged from −0.13 to 0.33; ranged from 0.331 to 0.876). Furthermore, we could not find any association of Ang-2 with the obtained clinical or radiologic parameters.

4. Discussion

Our rationale for initiating this study was the observation of increased Qalb in several subjects with CSF leakage that attended our clinic. Qalb is generally used to evaluate blood-CSF barrier function and was indeed more frequently increased in our CSF leakage cohort. Albumin (66–69 kDa) is the most abundant protein in CSF comprising up to 67% of total CSF proteins and exclusively originates from blood [16, 17]. To reach CSF, albumin must cross the blood-brain and blood-CSF barrier [16, 17]. However, it is speculated that albumin is not able to pass the blood-brain barrier because of the presence of tight junctions and needs to be extracted from the plasma via fenestrated endothelial cells and to enter the CSF by crossing the epithelial cells of the CP via transcellular transport [18]. There is also speculation that the crossing of the epithelial cells is a passive process and may depend on the size of the CP [17]. However, there is also the view that all molecules are able to pass the blood-brain barrier and that the extent of protein transfer depends on the molecular size-dependent diffusion [16]. Moreover, caution must be taken in interpreting the increase of Qalb regarding the integrity of the brain barriers since elevation of Qalb can also be construed as a decline in the CSF secretion rate/turnover [16].

Ang-2 forms multimeric structures composed of monomers of 55 kDa and the native form is mainly present as disulfide-linked dimers, but variable oligomeric forms may exist as well [19]. So far, it remains unknown whether the CSF Ang-2 is an extraction from plasma, secreted by ependymal cells, or both. There is increasing evidence that Ang-2 plays a role in various conditions of plasma leakage by loosening interendothelial junctions [7, 2022]. This activity at the “vessel wall” prompted us to hypothesize that the increase of Qalb is due to higher permeability of the blood-brain barrier and may explain increased Qalb values in subjects with CSF leakage syndrome. Consequently, we examined Ang-2 concentrations in serum and CSF of subjects with clinically definite and persistent CSF leakage syndrome. We found neither any difference in the mean CSF Ang-2, QAng-2, and QAng-2/Qalb as compared to our control cohort nor any correlation/association with the obtained CSF, clinical, or radiological parameters. In our study, the Ang-2 concentrations assessed in the CSF and serum concentrations are quite low suggesting quiescent ependymal or endothelial cells. The CSF Ang-2 levels of patients who suffered from subarachnoid hemorrhage have been reported to be 2.7-fold higher than control subjects, while only slightly elevated CSF Ang-2 concentrations have been observed in hypoxemic patients [12, 13]. In hypoxemic subjects, lactate that is abundantly released upon hypoxemia and known to activate receptor tyrosine kinases Axl, Tie2, and VEGF receptor 2 may have induced the release of Ang-2 as a compensatory response to hypoxia [23].

Among other factors, biomechanical stimulation has been shown to be a reliable trigger for the release of Ang-2 [24]. This is of particular interest since VEGF, whose function is mediated in corporation with Ang-2, has been implicated in the pathogenesis of hydrocephalus [25]. Accordingly, shear stress on arterial wall due to altered CSF flow or hemodynamics is considered as a possible trigger [26]. Since CSF leakage or, as a sort of biomechanical stimulation, pressure changes due to CSF leakage apparently do not lead to an increased release of Ang-2 into the CSF, the question of how and why Qalb increases in CSF leakage syndrome arises. In this regard, it should be mentioned that subjects with CSF leakage syndrome have been shown to exhibit a lower CSF flow as demonstrated by phase contrast-MRI [27]. We suggest that this is most probably the cause for the increase in Qalb which is supported by the fact that the concentrations of IgG, IgA, and IgM show that the molecular size-related selectivity of the barrier function is maintained in spite of blood-CSF barrier dysfunction (data not shown). Thus, the entry of plasma proteins via the leakage in CSF leakage syndrome seems rather unlikely. It should be mentioned that all CSF leakage subjects received an epidural blood patch treatment and intrathecal gd MR myelography provided a successful targeted approach in 9 of these subjects. The technique of intrathecal gd MR myelography is only available in specialized centers, while the epidural blood patch treatment is more common and mostly done in a nontargeted manner. It remains elusive whether Qalb can be used as a marker for successful nontargeted blood patching. Certainly, a constraining factor in this context is that CSF analyses are increasingly omitted since lumbar punctures are considered as a potential new source for a leakage. Further studies which will include CSF analyses and phase contrast-MRI before and after epidural blood patch treatment may shed light on the origin of the observed CSF changes in CSF leakage syndrome and whether Qalb can be used as a treatment marker.

Ang-2 and related molecules are of high interest for the CSF compartment and may help to elucidate our understanding of the mechanism of the brain barriers and CSF hemodynamics. In this pilot study, we did not find any involvement of Ang-2 in CSF leakage syndrome. There are several limitations inherent in this study. One limitation concerns the exploratory analysis of correlations which are post hoc exploratory analyses that need validation from independent studies. The second limitation is that the control group consisted of subjects who were not healthy. Therefore, a difference in CSF Ang-2 levels between healthy controls and subjects with CSF leakage syndrome cannot be excluded. The control group was deliberately chosen in order to find out whether other conditions, which may lead to an increase of Qalb, will be also accompanied by changes in CSF Ang-2 levels. Unexpectedly, we did not find any difference in CSF Ang-2 levels despite the significantly higher Qalb values and ratios of immunoglobulins in subjects with CSF leakage syndrome suggesting that secretion and elimination of Ang-2 are different from these proteins. Further limitations of the study are the small number of enrolled patients and that we assessed only a single marker of endothelial activation.

Conflict of Interests

All authors declare that there is no conflict of interests regarding the publication of this paper.

Authors’ Contribution

Corinna Trebst and Frank Donnerstag contributed equally to this paper.


  1. B. Mokri, “Spontaneous low pressure, low CSF volume headaches: spontaneous CSF leaks,” Headache, vol. 53, no. 7, pp. 1034–1053, 2013. View at: Publisher Site | Google Scholar
  2. W. I. Schievink, M. S. Schwartz, M. M. Maya, F. G. Moser, and T. D. Rozen, “Lack of causal association between spontaneous intracranial hypotension and cranial cerebrospinal fluid leaks,” Journal of Neurosurgery, vol. 116, no. 4, pp. 749–754, 2012. View at: Publisher Site | Google Scholar
  3. E. Wiesemann, G. Berding, F. Goetz, and A. Windhagen, “Spontaneous intracranial hypotension: correlation of imaging findings with clinical features,” European Neurology, vol. 56, no. 4, pp. 204–210, 2006. View at: Publisher Site | Google Scholar
  4. H. Wolburg and W. Paulus, “Choroid plexus: biology and pathology,” Acta Neuropathologica, vol. 119, no. 1, pp. 75–88, 2010. View at: Publisher Site | Google Scholar
  5. S. Esser, K. Wolburg, H. Wolburg, G. Breier, T. Kurzchalia, and W. Risau, “Vascular endothelial growth factor induces endothelial fenestrations in vitro,” The Journal of Cell Biology, vol. 140, no. 4, pp. 947–959, 1998. View at: Publisher Site | Google Scholar
  6. W. G. Roberts and G. E. Palade, “Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor,” Journal of Cell Science, vol. 108, part 6, pp. 2369–2379, 1995. View at: Google Scholar
  7. S. M. Parikh, T. Mammoto, A. Schultz et al., “Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans,” PLoS Medicine, vol. 3, no. 3, pp. 356–370, 2006. View at: Publisher Site | Google Scholar
  8. B. Nico, D. Mangieri, P. Corsi et al., “Vascular endothelial growth factor-A, vascular endothelial growth factor receptor-2 and angiopoietin-2 expression in the mouse choroid plexuses,” Brain Research, vol. 1013, no. 2, pp. 256–259, 2004. View at: Publisher Site | Google Scholar
  9. G. Scala and L. Maruccio, “Angiogenesis of buffalo choroid plexuses: structural and immunocytochemical study,” Microscopy Research and Technique, vol. 75, no. 8, pp. 1104–1112, 2012. View at: Publisher Site | Google Scholar
  10. N. Nourhaghighi, K. Teichert-Kuliszewska, J. Davis, D. J. Stewart, and S. Nag, “Altered expression of angiopoietins during blood-brain barrier breakdown and angiogenesis,” Laboratory Investigation, vol. 83, no. 8, pp. 1211–1222, 2003. View at: Publisher Site | Google Scholar
  11. S. Engelhardt, S. Patkar, and O. O. Ogunshola, “Cell-specific blood-brain barrier regulation in health and disease: a focus on hypoxia,” British Journal of Pharmacology, vol. 171, no. 5, pp. 1210–1230, 2014. View at: Publisher Site | Google Scholar
  12. C. Moreau, P. Gosset, V. Brunaud-Danel et al., “CSF profiles of angiogenic and inflammatory factors depend on the respiratory status of ALS patients,” Amyotrophic Lateral Sclerosis, vol. 10, no. 3, pp. 175–181, 2009. View at: Publisher Site | Google Scholar
  13. P. Chittiboina, V. Ganta, C. P. Monceaux, L. K. Scott, A. Nanda, and J. S. Alexander, “Angiopoietins as promising biomarkers and potential therapeutic targets in brain injury,” Pathophysiology, vol. 20, no. 1, pp. 15–21, 2013. View at: Publisher Site | Google Scholar
  14. T. Skripuletz, P. Schwenkenbecher, K. Pars et al., “Importance of follow-up cerebrospinal fluid analysis in cryptococcal meningoencephalitis,” Disease Markers, vol. 2014, Article ID 162576, 10 pages, 2014. View at: Publisher Site | Google Scholar
  15. S. Seyfert, V. Kunzmann, N. Schwertfeger, H. C. Koch, and A. Faulstich, “Determinants of lumbar CSF protein concentration,” Journal of Neurology, vol. 249, no. 8, pp. 1021–1026, 2002. View at: Publisher Site | Google Scholar
  16. H. Reiber, “Proteins in cerebrospinal fluid and blood: barriers, CSF flow rate and source-related dynamics,” Restorative Neurology and Neuroscience, vol. 21, no. 3-4, pp. 79–96, 2003. View at: Google Scholar
  17. R.-L. Chen, C. P.-C. Chen, and J. E. Preston, “Elevation of CSF albumin in old sheep: relations to CSF turnover and albumin extraction at blood-CSF barrier,” Journal of Neurochemistry, vol. 113, no. 5, pp. 1230–1239, 2010. View at: Publisher Site | Google Scholar
  18. Y. Balslev, K. M. Dziegielewska, K. Møllgård, and N. R. Saunders, “Intercellular barriers to and transcellular transfer of albumin in the fetal sheep brain,” Anatomy and Embryology, vol. 195, no. 3, pp. 229–236, 1997. View at: Publisher Site | Google Scholar
  19. K.-T. Kim, H.-H. Choi, M. O. Steinmetz et al., “Oligomerization and multimerization are critical for angiopoietin-1 to bind and phosphorylate Tie2,” The Journal of Biological Chemistry, vol. 280, no. 20, pp. 20126–20131, 2005. View at: Publisher Site | Google Scholar
  20. A. V. Benest, K. Kruse, S. Savant et al., “Angiopoietin-2 is critical for cytokine-induced vascular leakage,” PLoS ONE, vol. 8, no. 8, Article ID e70459, 2013. View at: Publisher Site | Google Scholar
  21. C. A. M. van de Weg, C. S. Pannuti, H.-J. van den Ham et al., “Serum angiopoietin-2 and soluble VEGF receptor 2 are surrogate markers for plasma leakage in patients with acute dengue virus infection,” Journal of Clinical Virology, vol. 60, no. 4, pp. 328–335, 2014. View at: Publisher Site | Google Scholar
  22. F. Roviezzo, S. Tsigkos, A. Kotanidou et al., “Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage,” The Journal of Pharmacology and Experimental Therapeutics, vol. 314, no. 2, pp. 738–744, 2005. View at: Publisher Site | Google Scholar
  23. G.-X. Ruan and A. Kazlauskas, “Lactate engages receptor tyrosine kinases Axl, Tie2, and vascular endothelial growth factor receptor 2 to activate phosphoinositide 3-kinase/AKT and promote angiogenesis,” The Journal of Biological Chemistry, vol. 288, no. 29, pp. 21161–21172, 2013. View at: Publisher Site | Google Scholar
  24. W. Goettsch, C. Gryczka, T. Korff et al., “Flow-dependent regulation of angiopoietin-2,” Journal of Cellular Physiology, vol. 214, no. 2, pp. 491–503, 2008. View at: Publisher Site | Google Scholar
  25. J. W. Shim, J. Sandlund, C. H. Han et al., “VEGF, which is elevated in the CSF of patients with hydrocephalus, causes ventriculomegaly and ependymal changes in rats,” Experimental Neurology, vol. 247, pp. 703–709, 2013. View at: Publisher Site | Google Scholar
  26. A. Shay-Salit, M. Shushy, E. Wolfovitz et al., “VEGF receptor 2 and the adherens junction as a mechanical transducer in vascular endothelial cells,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 14, pp. 9462–9467, 2002. View at: Publisher Site | Google Scholar
  27. H. Tung, Y.-C. Liao, C.-C. Wu et al., “Usefulness of phase-contrast magnetic resonance imaging for diagnosis and treatment evaluation in patients with SIH,” Cephalalgia, vol. 34, no. 8, pp. 584–593, 2014. View at: Publisher Site | Google Scholar

Copyright © 2015 Refik Pul et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Related articles

No related content is available yet for this article.
 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

No related content is available yet for this article.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.